AAPL   381.87 (+0.13%)
MSFT   213.41 (+0.27%)
FB   242.35 (-0.50%)
GOOGL   1,512.85 (+0.62%)
AMZN   3,120.55 (+1.28%)
NVDA   413.20 (+1.12%)
CGC   15.76 (-3.49%)
BABA   258.20 (+0.20%)
GE   6.67 (-2.77%)
TSLA   1,377.84 (+0.88%)
AMD   55.65 (+4.15%)
T   29.48 (-3.22%)
DIS   116.85 (+0.16%)
BA   174.91 (-2.87%)
AAPL   381.87 (+0.13%)
MSFT   213.41 (+0.27%)
FB   242.35 (-0.50%)
GOOGL   1,512.85 (+0.62%)
AMZN   3,120.55 (+1.28%)
NVDA   413.20 (+1.12%)
CGC   15.76 (-3.49%)
BABA   258.20 (+0.20%)
GE   6.67 (-2.77%)
TSLA   1,377.84 (+0.88%)
AMD   55.65 (+4.15%)
T   29.48 (-3.22%)
DIS   116.85 (+0.16%)
BA   174.91 (-2.87%)
AAPL   381.87 (+0.13%)
MSFT   213.41 (+0.27%)
FB   242.35 (-0.50%)
GOOGL   1,512.85 (+0.62%)
AMZN   3,120.55 (+1.28%)
NVDA   413.20 (+1.12%)
CGC   15.76 (-3.49%)
BABA   258.20 (+0.20%)
GE   6.67 (-2.77%)
TSLA   1,377.84 (+0.88%)
AMD   55.65 (+4.15%)
T   29.48 (-3.22%)
DIS   116.85 (+0.16%)
BA   174.91 (-2.87%)
AAPL   381.87 (+0.13%)
MSFT   213.41 (+0.27%)
FB   242.35 (-0.50%)
GOOGL   1,512.85 (+0.62%)
AMZN   3,120.55 (+1.28%)
NVDA   413.20 (+1.12%)
CGC   15.76 (-3.49%)
BABA   258.20 (+0.20%)
GE   6.67 (-2.77%)
TSLA   1,377.84 (+0.88%)
AMD   55.65 (+4.15%)
T   29.48 (-3.22%)
DIS   116.85 (+0.16%)
BA   174.91 (-2.87%)
Log in

NASDAQ:FGENFibroGen Stock Price, Forecast & News

$41.35
-0.56 (-1.34 %)
(As of 07/9/2020 11:02 AM ET)
Add
Compare
Today's Range
$41.35
Now: $41.35
$42.11
50-Day Range
$32.64
MA: $37.94
$43.50
52-Week Range
$22.65
Now: $41.35
$48.95
Volume60,313 shs
Average Volume762,108 shs
Market Capitalization$3.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.58
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Read More
FibroGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.09 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$256.58 million
Book Value$6.14 per share

Profitability

Net Income$-76,970,000.00

Miscellaneous

Employees461
Market Cap$3.68 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

How has FibroGen's stock been impacted by COVID-19 (Coronavirus)?

FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FGEN shares have increased by 16.8% and is now trading at $41.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of FibroGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen.

When is FibroGen's next earnings date?

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for FibroGen.

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.50. The biopharmaceutical company earned $24.40 million during the quarter, compared to analyst estimates of $72.58 million. FibroGen had a negative net margin of 42.75% and a negative return on equity of 19.32%. FibroGen's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.53) earnings per share. View FibroGen's earnings history.

What price target have analysts set for FGEN?

5 Wall Street analysts have issued 12 month price objectives for FibroGen's stock. Their forecasts range from $40.00 to $80.00. On average, they expect FibroGen's share price to reach $57.60 in the next year. This suggests a possible upside of 39.3% from the stock's current price. View analysts' price targets for FibroGen.

Has FibroGen been receiving favorable news coverage?

News coverage about FGEN stock has trended negative this week, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. FibroGen earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about FibroGen.

Who are some of FibroGen's key competitors?

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

Who are FibroGen's key executives?

FibroGen's management team includes the following people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
  • Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
  • Dr. K. Peony Yu, Chief Medical Officer (Age 57)
  • Mr. Julian N. Stern, Sec. (Age 94)
  • Dr. Barry A. Berkowitz, Founder

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.03%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View institutional ownership trends for FibroGen.

Which institutional investors are selling FibroGen stock?

FGEN stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff, and Thomas F Kearns Jr. View insider buying and selling activity for FibroGen.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $41.35.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.68 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

What is FibroGen's official website?

The official website for FibroGen is www.fibrogen.com.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.